Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 3/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.41 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.41 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.41 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.41 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.41 |
| ▸ | CPN1 | P15169 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
| ▸ | GABRD | O14764 | 1/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6264076 | 0.88 | GABRA5 (0.45) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| Trifluoroacetic Acid SCHEMBL23044797 | 0.81 | GABRA5 (0.40) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| Trifluoroacetic Acid SCHEMBL28044634 | 0.79 | GABRA5 (0.43) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| Trifluoroacetic Acid SCHEMBL13254839 | 0.79 | GABRA5 (0.43) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| Trifluoroacetic Acid SCHEMBL6632396 | 0.77 | EPHX1 (0.45) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| Trifluoroacetic Acid SCHEMBL6629104 | 0.77 | EPHX1 (0.45) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| Trifluoroacetic Acid SCHEMBL6626871 | 0.77 | EPHX1 (0.45) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| Trifluoroacetic Acid SCHEMBL2997803 | 0.75 | GABRA5 (0.40) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL11698795 | 0.75 | GABRA5 (0.52) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| Trifluoroacetic Acid SCHEMBL38661436 | 0.75 | GABRA5 (0.41) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2025-01-23 | — | — | US | disclosed |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2024-08-13 | — | — | US | disclosed |
| EP-4098654-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-114533729-A | Glucosylceramide synthase inhibitors | 建新公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220073508-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2022-03-10 | — | — | US | disclosed |
| EP-2895484-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2022-02-23 | — | — | EP | disclosed |
| CN-108864076-B | Glucosylceramide synthase inhibitors | 建新公司 | 2022-02-11 | — | — | CN | disclosed |
| US-11008316-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2021-05-18 | — | — | US | disclosed |
| CN-105073745-B | glucosylceramide synthase inhibitors | 建新公司 | 2018-06-29 | — | — | CN | disclosed |
| US-20180065957-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2018-03-08 | — | — | US | disclosed |
| WO-2003070728-A2 | AZABICYCLO-SUBSTITUTED BENZOYLAMIDES AND THIOAMIDES FOR TREATMENT OF CNS-RELATED DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003070731-A2 | AZABICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20030153595-A1 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-08-14 | — | — | US | disclosed |
| US-20030130305-A1 | Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-07-10 | — | — | US | disclosed |
| WO-2003042210-A1 | AZABICYCLIC-PHENYL-FUSED-HETEROCYCLIC COMPOUNDS AND THEIR USE AS ALPHA7 NACHR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-05-22 | — | — | WO | disclosed |
| WO-2003040147-A1 | AZABICYCLIC-SUBSTITUTED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE__________________________________________________________________________________________________________________________ | PHARMACIA & UPJOHN COMPANY (US) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003037896-A1 | N-AZABICYCLO-SUBSTITUTED HETERO-BICYCLIC CARBOXAMIDES AS NACHR AGONISTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-05-08 | — | — | WO | disclosed |
| WO-2003029252-A1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-10 | — | — | WO | disclosed |
| US-20030055043-A1 | Substituted azabicyclic moieties for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-03-20 | — | — | US | disclosed |
| WO-2002085901-A1 | SUBSTITUTED AZABICYCLIC MOIETIES FOR THE TREATMENT OF DISEASE (NICOTINIC ACETHYLCHOLINE RECEPTOR AGONISTS) | PHARMACIA & UPJOHN COMPANY (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130305-A1 | Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease | TPMT, PAICS, MALT1 | GABRA5 857/4885GABRB2 770/4885SLC6A1 1018/4885 |
| US-20030153595-A1 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | MALT1, TPMT, ABCB1 | GABRA5 402/4885GABRB2 354/4885SLC6A1 431/4885 |
| US-20180065957-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | GABRA5 3494/4885GABRB2 3796/4885SLC6A1 2722/4885 |
| US-11008316-B2 | Glucosylceramide synthase inhibitors | GBA1, GBA2, GAA | GABRA5 3880/4885GABRB2 3984/4885SLC6A1 2811/4885 |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GBA1, GBA2, GALC | GABRA5 3158/4885GABRB2 3794/4885SLC6A1 1107/4885 |
| US-20030055043-A1 | Substituted azabicyclic moieties for the treatment of disease | CHRNA1, CHRNA7, CHRNA5 | GABRA5 283/4885GABRB2 281/4885SLC6A1 533/4885 |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | GABRA5 3494/4885GABRB2 3796/4885SLC6A1 2722/4885 |
| US-20220073508-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | GABRA5 3494/4885GABRB2 3796/4885SLC6A1 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.